RCS - Oxford Biomedica PLC - Oxford Biomedica launches TetraVecta system

Oxford BioMedicaAnnouncement

15/05/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230515:nRSO3287Za&default-theme=true

RNS Number : 3287Z  Oxford Biomedica PLC  15 May 2023

 

Oxford Biomedica launches TetraVecta(TM) - the next generation lentiviral
vector system

 

Oxford, UK - 15 May 2023: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica"
or "the Company"), a quality and innovation-led viral vector CDMO, today
announces the launch of its 4(th) generation lentiviral vector delivery
system, TetraVecta(TM). This state-of-the-art technology developed at Oxford
Biomedica elevates the quality, potency and packaging capacity of lentiviral
vectors, while incorporating new and enhanced safety features, adding to the
Company's client offering and its leading LentiVector(®) platform.

 

The TetraVecta(TM) system significantly enhances the development and
manufacture of safer and more effective lentiviral vector-based therapies.
This enables cell and gene therapy companies to overcome previous barriers in
therapeutic development, due to the size, complexity, or interference of the
payload to be delivered. This cutting-edge new technology paves the way for
genuine plug and play manufacturing and supports Oxford Biomedica's clients in
delivering their innovative and life-changing treatments to patients. The
features of the TetraVecta(TM) system can also be used to accelerate the
development and adoption of in vivo gene therapies (directly via intravenous
injection or to a specific organ). In addition to its broad applications, the
TetraVecta(TM) system has demonstrated its versatile potential by supporting
the creation of high-titre stable producer cell lines for previously
unachievable payloads such as Chimeric Antigen Receptor (CAR) constructs for
CAR-T therapy.

 

Oxford Biomedica launched the TetraVecta(TM) system following years of
development and on the basis of detailed understanding of specific industry
challenges. The TetraVecta(TM) system has already proven successful in pilot
projects and is now being rolled out to support the development of more
complex advanced therapies.

 

Oxford Biomedica will be presenting the TetraVecta™ system at the ASGCT
26(th) Annual Meeting in Los Angeles, California, on Wednesday, 17 May 2023 at
12.00pm PT.

 

Kyriacos Mitrophanous, Chief Scientific Officer of Oxford Biomedica, said:
"The launch of The TetraVecta(TM) system demonstrates our commitment to
investing in innovation in the cell and gene therapy field. This next
generation lentiviral vector system empowers our clients to overcome
previous-generation vector limitations and develop life-saving treatments. By
addressing critical industry challenges and streamlining the development
process, we are enabling our clients to shape the future of gene therapy. The
TetraVecta(TM) system has the potential to make a lasting impact on the
industry. Our ultimate aim is to constantly provide clients with high quality,
cutting-edge technology, supporting their efforts to bring transformative
therapies to patients in need."

 

-Ends-

 

Enquiries:

 

 

Oxford Biomedica plc:

 

Sebastien Ribault, Chief Commercial Officer - T: +44 (0)1865 783 000 / E:
partnering@oxb.com

Taylor Boyd, VP, Head of IR - T: +1 (984) 268 8488 / E: ir@oxb.com

Sophia Bolhassan, VP, Head of Corporate Affairs: +44 (0) 7394 562 425 / E:
ir@oxb.com

 

Consilium Strategic Communications:

 

T: +44 (0)20 3709 5700 / E: oxfordbiomedica@consilium-comms.com

Mary-Jane Elliott / Matthew Neal / Davide Salvi

 

 

About Oxford Biomedica

 

Oxford Biomedica (LSE: OXB) is a quality and innovation-led viral vector CDMO
with a mission to enable its clients to deliver life changing therapies to
patients around the world.

 

One of the original pioneers in cell and gene therapy, the Company has more
than 25 years of experience in viral vectors; the driving force behind the
majority of gene therapies. The Company collaborates with some of the world's
most innovative pharmaceutical and biotechnology companies, providing viral
vector development and manufacturing expertise in lentivirus, adeno-associated
virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class
capabilities span from early-stage development to commercialisation. These
capabilities are supported by robust quality-assurance systems, analytical
methods and depth of regulatory expertise.

 

Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It
has locations across Oxfordshire, UK and a US-based subsidiary, Oxford
Biomedica Solutions, based near Boston, MA, US. Learn more at www.oxb.com,
www.oxbsolutions.com, and follow us on LinkedIn, Twitter and YouTube.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRASFEFWEEDSEDI